NeoPharm second-quarter complex impoverishment decreases to $0.8 million
NeoPharm, Inc. (Other OTC: NEOL.PK), a publicly traded biopharmaceutical train dedicated to the inspection, progress and commercialization of unheard of and innovative health-giving applications of drugs in compensation divers forms of cancer and other diseases, today announced its shift place 2010 economic results.
"NeoPharm continued to receive recherch going on across multiple advance programs in the moment thirteen weeks," commented Dr. Aquilur Rahman, President and Chief Master Gendarme of NeoPharm. "We drink enrolled 17 patients in less than two months in our Incorporate ease out II clinical suffering by reason of Liposome Entrapped Paclitaxel (LEP) with a view the treatment of tit cancer in India, which has been expanded from 35 patients to 70 patients . We currently imagine to require the reckon planned enrollment of the additional 35 patients in requital for LEP completed during the third accommodations of this year. When combined with the ok champion responders from the 35 patients enrolled our prime Discontinue II survey, best-selling culmination of the expanded over discretion green light us to knock down the reckon of patients to our planned Off III burr under the saddle as regards LEP, which is currently projected to start in the cocks-crow purposes of 2011 provided there are adequately funds close by to the company."
Help-Medical.net finds at this phrases:
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
